{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:20:26Z","timestamp":1787062826518,"version":"build-2736575974"},"reference-count":146,"publisher":"IMR Press","issue":"11","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32160212"],"award-info":[{"award-number":["32160212"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is the most common cause of dementia. The two major hallmarks of this disease are extracellular amyloid plaques and intracellular neurofibrillary tangles in the brain, accompanied by loss of neurons and synapses. The plaques and tangles mainly consist of amyloid-\u03b2 (A\u03b2) and tau protein, respectively. Most of the therapeutic strategies for AD to date have focused on A\u03b2. However, there is still no effective therapy available. In recent years, the clinical therapeutic failure of targeting A\u03b2 pathology has resulted in increased interest towards tau-based therapeutics. In the current review, we focus on the research progress regarding the pathological mechanisms of tau protein in this disease and discuss tau-targeting therapeutic strategies.<\/jats:p>","DOI":"10.31083\/j.jin2311197","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:34:00Z","timestamp":1732707240000},"source":"Crossref","is-referenced-by-count":11,"title":["Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease"],"prefix":"10.31083","volume":"23","author":[{"given":"Futao","family":"Zhou","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Gannan Medical University, 341000 Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhao","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Gannan Medical University, 341000 Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyan","family":"Sun","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Gannan Medical University, 341000 Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjiao","family":"Chen","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Gannan Medical University, 341000 Ganzhou, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ren R, Qi J, Lin S, Liu X, Yin P, Wang Z, et al. The China Alzheimer Report 2022. General Psychiatry. 2022; 35: e100751.","DOI":"10.1136\/gpsych-2022-100751"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2021 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2021; 17: 327\u2013406.","DOI":"10.1002\/alz.12328"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature Reviews. Drug Discovery. 2022; 21: 306\u2013318.","DOI":"10.1038\/s41573-022-00391-w"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Robinson AC, Davidson YS, Horan MA, Pendleton N, Mann DMA. Pathological Correlates of Cognitive Impairment in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. Journal of Alzheimer\u2019s Disease: JAD. 2018; 64: 483\u2013496.","DOI":"10.3233\/JAD-180171"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Jucker M, Walker LC. Alzheimer\u2019s disease: From immunotherapy to immunoprevention. Cell. 2023; 186: 4260\u20134270.","DOI":"10.1016\/j.cell.2023.08.021"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Rother C, Uhlmann RE, M\u00fcller SA, Schelle J, Skodras A, Oberm\u00fcller U, et al. Experimental evidence for temporal uncoupling of brain A\u03b2 deposition and neurodegenerative sequelae. Nature Communications. 2022; 13: 7333.","DOI":"10.1038\/s41467-022-34538-5"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Goldsworthy MR, Vallence AM. The role of \u03b2-amyloid in alzheimer\u2019s disease-related neurodegeneration. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2013; 33: 12910\u201312911.","DOI":"10.1523\/JNEUROSCI.2252-13.2013"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Thal DR, Tom\u00e9 SO. The central role of tau in Alzheimer\u2019s disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Research Bulletin. 2022; 190: 204\u2013217.","DOI":"10.1016\/j.brainresbull.2022.10.006"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nature Reviews. Neuroscience. 2016; 17: 5\u201321.","DOI":"10.1038\/nrn.2015.1"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hasegawa M, Watanabe S, Kondo H, Akiyama H, Mann DMA, Saito Y, et al. 3R and 4R tau isoforms in paired helical filaments in Alzheimer\u2019s disease. Acta Neuropathologica. 2014; 127: 303\u2013305.","DOI":"10.1007\/s00401-013-1191-9"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Zhong Q, Congdon EE, Nagaraja HN, Kuret J. Tau isoform composition influences rate and extent of filament formation. The Journal of Biological Chemistry. 2012; 287: 20711\u201320719.","DOI":"10.1074\/jbc.M112.364067"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Caceres A, Kosik KS. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons. Nature. 1990; 343: 461\u2013463.","DOI":"10.1038\/343461a0"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bi M, Gladbach A, van Eersel J, Ittner A, Przybyla M, van Hummel A, et al. Tau exacerbates excitotoxic brain damage in an animal model of stroke. Nature Communications. 2017; 8: 473.","DOI":"10.1038\/s41467-017-00618-0"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine. 2017; 9: eaag0481.","DOI":"10.1126\/scitranslmed.aag0481"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model. Science (New York, N.Y.). 2007; 316: 750\u2013754.","DOI":"10.1126\/science.1141736"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Kimura T, Whitcomb DJ, Jo J, Regan P, Piers T, Heo S, et al. Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2013; 369: 20130144.","DOI":"10.1098\/rstb.2013.0144"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Hu Z, Ondrejcak T, Yu P, Zhang Y, Yang Y, Klyubin I, et al. Do tau-synaptic long-term depression interactions in the hippocampus play a pivotal role in the progression of Alzheimer\u2019s disease? Neural Regeneration Research. 2023; 18: 1213\u20131219.","DOI":"10.4103\/1673-5374.360166"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer\u2019s disease mouse models. Cell. 2010; 142: 387\u2013397.","DOI":"10.1016\/j.cell.2010.06.036"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ant\u00f3n-Fern\u00e1ndez A, Vall\u00e9s-Saiz L, Avila J, Hern\u00e1ndez F. Neuronal nuclear tau and neurodegeneration. Neuroscience. 2023; 518: 178\u2013184.","DOI":"10.1016\/j.neuroscience.2022.07.015"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Loomis PA, Howard TH, Castleberry RP, Binder LI. Identification of nuclear tau isoforms in human neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87: 8422\u20138426.","DOI":"10.1073\/pnas.87.21.8422"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Brady RM, Zinkowski RP, Binder LI. Presence of tau in isolated nuclei from human brain. Neurobiology of Aging. 1995; 16: 479\u2013486.","DOI":"10.1016\/0197-4580(95)00023-8"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Sultan A, Nesslany F, Violet M, B\u00e9gard S, Loyens A, Talahari S, et al. Nuclear tau, a key player in neuronal DNA protection. The Journal of Biological Chemistry. 2011; 286: 4566\u20134575.","DOI":"10.1074\/jbc.M110.199976"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Violet M, Delattre L, Tardivel M, Sultan A, Chauderlier A, Caillierez R, et al. A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Frontiers in Cellular Neuroscience. 2014; 8: 84.","DOI":"10.3389\/fncel.2014.00084"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Maina MB, Bailey LJ, Wagih S, Biasetti L, Pollack SJ, Quinn JP, et al. The involvement of tau in nucleolar transcription and the stress response. Acta Neuropathologica Communications. 2018; 6: 70.","DOI":"10.1186\/s40478-018-0565-6"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Bukar Maina M, Al-Hilaly YK, Serpell LC. Nuclear Tau and Its Potential Role in Alzheimer\u2019s Disease. Biomolecules. 2016; 6: 9.","DOI":"10.3390\/biom6010009"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Song L, Oseid DE, Wells EA, Coaston T, Robinson AS. Heparan Sulfate Proteoglycans (HSPGs) Serve as the Mediator Between Monomeric Tau and Its Subsequent Intracellular ERK1\/2 Pathway Activation. Journal of Molecular Neuroscience: MN. 2022; 72: 772\u2013791.","DOI":"10.1007\/s12031-021-01943-2"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nature Reviews. Molecular Cell Biology. 2020; 21: 607\u2013632.","DOI":"10.1038\/s41580-020-0255-7"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Leugers CJ, Lee G. Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. The Journal of Biological Chemistry. 2010; 285: 19125\u201319134.","DOI":"10.1074\/jbc.M110.105387"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Marciniak E, Leboucher A, Caron E, Ahmed T, Tailleux A, Dumont J, et al. Tau deletion promotes brain insulin resistance. The Journal of Experimental Medicine. 2017; 214: 2257\u20132269.","DOI":"10.1084\/jem.20161731"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Kanaan NM, Morfini G, Pigino G, LaPointe NE, Andreadis A, Song Y, et al. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiology of Aging. 2012; 33: 826.e15\u2013826.e30.","DOI":"10.1016\/j.neurobiolaging.2011.06.006"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Mueller RL, Combs B, Alhadidy MM, Brady ST, Morfini GA, Kanaan NM. Tau: A Signaling Hub Protein. Frontiers in Molecular Neuroscience. 2021; 14: 647054.","DOI":"10.3389\/fnmol.2021.647054"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Brunello CA, Merezhko M, Uronen RL, Huttunen HJ. Mechanisms of secretion and spreading of pathological tau protein. Cellular and Molecular Life Sciences: CMLS. 2020; 77: 1721\u20131744.","DOI":"10.1007\/s00018-019-03349-1"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Merezhko M, Brunello CA, Yan X, Vihinen H, Jokitalo E, Uronen RL, et al. Secretion of Tau via an Unconventional Non-vesicular Mechanism. Cell Reports. 2018; 25: 2027\u20132035.e4.","DOI":"10.1016\/j.celrep.2018.10.078"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Katsinelos T, Zeitler M, Dimou E, Karakatsani A, M\u00fcller HM, Nachman E, et al. Unconventional Secretion Mediates the Trans-cellular Spreading of Tau. Cell Reports. 2018; 23: 2039\u20132055.","DOI":"10.1016\/j.celrep.2018.04.056"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Merezhko M, Uronen RL, Huttunen HJ. The Cell Biology of Tau Secretion. Frontiers in Molecular Neuroscience. 2020; 13: 569818.","DOI":"10.3389\/fnmol.2020.569818"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Guan PP, Wang P. The Involvement of Post-Translational Modifications in Regulating the Development and Progression of Alzheimer\u2019s Disease. Molecular Neurobiology. 2023; 60: 3617\u20133632.","DOI":"10.1007\/s12035-023-03277-z"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Iqbal K. Tau and Alzheimer\u2019s disease: Past, present and future. Cytoskeleton (Hoboken, N.J.). 2024; 81: 116\u2013121.","DOI":"10.1002\/cm.21822"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Wegmann S, Medalsy ID, Mandelkow E, M\u00fcller DJ. The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110: E313\u2013E321.","DOI":"10.1073\/pnas.1212100110"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease. Annals of Neurology. 1997; 41: 17\u201324.","DOI":"10.1002\/ana.410410106"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Perez-Nievas BG, Stein TD, Tai HC, Dols-Icardo O, Scotton TC, Barroeta-Espar I, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer\u2019s pathology. Brain: a Journal of Neurology. 2013; 136: 2510\u20132526.","DOI":"10.1093\/brain\/awt171"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nature Reviews. Neurology. 2016; 12: 15\u201327.","DOI":"10.1038\/nrneurol.2015.225"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Basheer N, Smolek T, Hassan I, Liu F, Iqbal K, Zilka N, et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From preclinical studies to the clinical trials. Molecular Psychiatry. 2023; 28: 2197\u20132214.","DOI":"10.1038\/s41380-023-02113-z"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, et al. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. The Journal of Biological Chemistry. 2010; 285: 30851\u201330860.","DOI":"10.1074\/jbc.M110.110957"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993; 11: 153\u2013163.","DOI":"10.1016\/0896-6273(93)90279-Z"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Cho JH, Johnson GVW. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau\u2019s ability to bind and stabilize microtubules. Journal of Neurochemistry. 2004; 88: 349\u2013358.","DOI":"10.1111\/j.1471-4159.2004.02155.x"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer\u2019s disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993; 10: 1089\u20131099.","DOI":"10.1016\/0896-6273(93)90057-X"},{"key":"ref47","unstructured":"Su\u00e1rez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodr\u00edguez J, Mil\u00e0-Alom\u00e0 M, Gispert JD, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in A\u03b2 pathology are detected. EMBO Molecular Medicine. 2020; 12: e12921."},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Turab Naqvi AA, Hasan GM, Hassan MI. Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer\u2019s Disease. Current Topics in Medicinal Chemistry. 2020; 20: 1059\u20131073.","DOI":"10.2174\/1568026620666200106125910"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D. Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochimica et Biophysica Acta. Molecular Cell Research. 2020; 1867: 118664.","DOI":"10.1016\/j.bbamcr.2020.118664"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Koike R, Takaichi Y, Soeda Y, Takashima A. Memory formation in old age requires GSK-3\u03b2. Aging Brain. 2021; 1: 100022.","DOI":"10.1016\/j.nbas.2021.100022"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Lee SJ, Chung YH, Joo KM, Lim HC, Jeon GS, Kim D, et al. Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats. Neuroscience Letters. 2006; 409: 134\u2013139.","DOI":"10.1016\/j.neulet.2006.09.026"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer\u2019s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathology and Applied Neurobiology. 2007; 33: 43\u201355.","DOI":"10.1111\/j.1365-2990.2006.00795.x"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002; 34: 509\u2013519.","DOI":"10.1016\/S0896-6273(02)00706-7"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"P\u00e9rez M, Hern\u00e1ndez F, G\u00f3mez-Ramos A, Smith M, Perry G, Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. European Journal of Biochemistry. 2002; 269: 1484\u20131489.","DOI":"10.1046\/j.1432-1033.2002.02794.x"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Song L, Oseid DE, Wells EA, Robinson AS. The Interplay between GSK3\u03b2 and Tau Ser262 Phosphorylation during the Progression of Tau Pathology. International Journal of Molecular Sciences. 2022; 23: 11610.","DOI":"10.3390\/ijms231911610"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Piedrahita D, Hern\u00e1ndez I, L\u00f3pez-Tob\u00f3n A, Fedorov D, Obara B, Manjunath BS, et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer\u2019s mice. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2010; 30: 13966\u201313976.","DOI":"10.1523\/JNEUROSCI.3637-10.2010"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Sundaram JR, Poore CP, Sulaimee NHB, Pareek T, Asad ABMA, Rajkumar R, et al. Specific inhibition of p25\/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2013; 33: 334\u2013343.","DOI":"10.1523\/JNEUROSCI.3593-12.2013"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Saito T, Oba T, Shimizu S, Asada A, Iijima KM, Ando K. Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262. Human Molecular Genetics. 2019; 28: 3062\u20133071.","DOI":"10.1093\/hmg\/ddz120"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Xu M, Huang Y, Song P, Huang Y, Huang W, Zhang HT, et al. AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain. Journal of Alzheimer\u2019s Disease: JAD. 2019; 70: 573\u2013585.","DOI":"10.3233\/JAD-190099"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Schn\u00f6der L, Gasparoni G, Nordstr\u00f6m K, Schottek A, Tomic I, Christmann A, et al. Neuronal deficiency of p38\u03b1-MAPK ameliorates symptoms and pathology of APP or Tau-transgenic Alzheimer\u2019s mouse models. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2020; 34: 9628\u20139649.","DOI":"10.1096\/fj.201902731RR"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Maphis N, Jiang S, Xu G, Kokiko-Cochran ON, Roy SM, Van Eldik LJ, et al. Selective suppression of the \u03b1 isoform of p38 MAPK rescues late-stage tau pathology. Alzheimer\u2019s Research & Therapy. 2016; 8: 54.","DOI":"10.1186\/s13195-016-0221-y"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Liu X, Lai LY, Chen JX, Li X, Wang N, Zhou LJ, et al. An inhibitor with GSK3\u03b2 and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer\u2019s disease. Neuropharmacology. 2023; 232: 109525.","DOI":"10.1016\/j.neuropharm.2023.109525"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Ryoo SR, Jeong HK, Radnaabazar C, Yoo JJ, Cho HJ, Lee HW, et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. The Journal of Biological Chemistry. 2007; 282: 34850\u201334857.","DOI":"10.1074\/jbc.M707358200"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Zhu B, Parsons T, Foley C, Shaw Y, Dunckley T, Hulme C, et al. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-\u03b2, Tau and DYRK1A neurotoxicity. Scientific Reports. 2022; 12: 15847.","DOI":"10.1038\/s41598-022-19967-y"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Wu YW, HuangFu WC, Lin TE, Peng CH, Tu HJ, Sung TY, et al. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule. International Journal of Biological Macromolecules. 2024; 259: 129074.","DOI":"10.1016\/j.ijbiomac.2023.129074"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Melchior B, Mittapalli GK, Lai C, Duong-Polk K, Stewart J, G\u00fcner B, et al. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer\u2019s disease. Aging Cell. 2019; 18: e13000.","DOI":"10.1111\/acel.13000"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Terro F. Tau protein phosphatases in Alzheimer\u2019s disease: the leading role of PP2A. Ageing Research Reviews. 2013; 12: 39\u201349.","DOI":"10.1016\/j.arr.2012.06.008"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Wang X, Blanchard J, Tung YC, Grundke-Iqbal I, Iqbal K. Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats. Journal of Alzheimer\u2019s Disease: JAD. 2015; 45: 423\u2013435.","DOI":"10.3233\/JAD-142403"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Zhou XW, Gustafsson JA, Tanila H, Bjorkdahl C, Liu R, Winblad B, et al. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiology of Disease. 2008; 31: 386\u2013394.","DOI":"10.1016\/j.nbd.2008.05.013"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Sontag JM, Sontag E. Protein phosphatase 2A dysfunction in Alzheimer\u2019s disease. Frontiers in Molecular Neuroscience. 2014; 7: 16.","DOI":"10.3389\/fnmol.2014.00016"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Yao PJ, Coleman PD. Reduction of O-linked N-acetylglucosamine-modified assembly protein-3 in Alzheimer\u2019s disease. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 1998; 18: 2399\u20132411.","DOI":"10.1523\/JNEUROSCI.18-07-02399.1998"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Ansari SA, Emerald BS. The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration. Frontiers in Neuroscience. 2019; 13: 473.","DOI":"10.3389\/fnins.2019.00473"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Huang R, Tian S, Zhang H, Zhu W, Wang S. Chronic hyperglycemia induces tau hyperphosphorylation by downregulating OGT-involved O-GlcNAcylation in vivo and in vitro. Brain Research Bulletin. 2020; 156: 76\u201385.","DOI":"10.1016\/j.brainresbull.2020.01.006"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Huang CW, Rust NC, Wu HF, Hart GW. Altered O-GlcNAcylation and mitochondrial dysfunction, a molecular link between brain glucose dysregulation and sporadic Alzheimer\u2019s disease. Neural Regeneration Research. 2023; 18: 779\u2013783.","DOI":"10.4103\/1673-5374.354515"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Cantrelle FX, Loyens A, Trivelli X, Reimann O, Despres C, Gandhi NS, et al. Phosphorylation and O-GlcNAcylation of the PHF-1 Epitope of Tau Protein Induce Local Conformational Changes of the C-Terminus and Modulate Tau Self-Assembly Into Fibrillar Aggregates. Frontiers in Molecular Neuroscience. 2021; 14: 661368.","DOI":"10.3389\/fnmol.2021.661368"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ryan P, Xu M, Davey AK, Danon JJ, Mellick GD, Kassiou M, et al. O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. ACS Chemical Neuroscience. 2019; 10: 2209\u20132221.","DOI":"10.1021\/acschemneuro.9b00143"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Pan D, Gu JH, Zhang J, Hu Y, Liu F, Iqbal K, et al. Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice. Journal of Alzheimer\u2019s Disease: JAD. 2021; 81: 273\u2013286.","DOI":"10.3233\/JAD-201450"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Wang X, Li W, Marcus J, Pearson M, Song L, Smith K, et al. MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy. The Journal of Pharmacology and Experimental Therapeutics. 2020; 374: 252\u2013263.","DOI":"10.1124\/jpet.120.266122"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Hastings NB, Wang X, Song L, Butts BD, Grotz D, Hargreaves R, et al. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Molecular Neurodegeneration. 2017; 12: 39.","DOI":"10.1186\/s13024-017-0181-0"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Rostgaard N, Jul PH, Garmer M, Volbracht C. Increasing O-GlcNAcylation Attenuates tau Hyperphosphorylation and Behavioral Impairment in rTg4510 Tauopathy Mice. Journal of Integrative Neuroscience. 2023; 22: 135.","DOI":"10.31083\/j.jin2205135"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010; 67: 953\u2013966.","DOI":"10.1016\/j.neuron.2010.08.044"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Min SW, Sohn PD, Li Y, Devidze N, Johnson JR, Krogan NJ, et al. SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2018; 38: 3680\u20133688.","DOI":"10.1523\/JNEUROSCI.2369-17.2018"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Wang J, Zhou F, Xiong CE, Wang GP, Chen LW, Zhang YT, et al. Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer\u2019s disease. Aging. 2023; 15: 9464\u20139478.","DOI":"10.18632\/aging.205015"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Wegmann S, Eftekharzadeh B, Tepper K, Zoltowska KM, Bennett RE, Dujardin S, et al. Tau protein liquid-liquid phase separation can initiate tau aggregation. The EMBO Journal. 2018; 37: e98049.","DOI":"10.15252\/embj.201798049"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Friedhoff P, von Bergen M, Mandelkow EM, Davies P, Mandelkow E. A nucleated assembly mechanism of Alzheimer paired helical filaments. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95: 15712\u201315717.","DOI":"10.1073\/pnas.95.26.15712"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. International Journal of Molecular Sciences. 2014; 15: 4671\u20134713.","DOI":"10.3390\/ijms15034671"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Moloney CM, Lowe VJ, Murray ME. Visualization of neurofibrillary tangle maturity in Alzheimer\u2019s disease: A clinicopathologic perspective for biomarker research. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2021; 17: 1554\u20131574.","DOI":"10.1002\/alz.12321"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Congdon EE, Duff KE. Is tau aggregation toxic or protective? Journal of Alzheimer\u2019s Disease. 2008; 14: 453\u2013457.","DOI":"10.3233\/JAD-2008-14415"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Molecular Neurodegeneration. 2011; 6: 39.","DOI":"10.1186\/1750-1326-6-39"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry. 2007; 46: 3856\u20133861.","DOI":"10.1021\/bi061359o"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Kundel F, De S, Flagmeier P, Horrocks MH, Kjaergaard M, Shammas SL, et al. Hsp70 Inhibits the Nucleation and Elongation of Tau and Sequesters Tau Aggregates with High Affinity. ACS Chemical Biology. 2018; 13: 636\u2013646.","DOI":"10.1021\/acschembio.7b01039"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Weickert S, Wawrzyniuk M, John LH, R\u00fcdiger SGD, Drescher M. The mechanism of Hsp90-induced oligomerizaton of Tau. Science Advances. 2020; 6: eaax6999.","DOI":"10.1126\/sciadv.aax6999"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Criado-Marrero M, Gebru NT, Blazier DM, Gould LA, Baker JD, Beaulieu-Abdelahad D, et al. Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice. Acta Neuropathologica Communications. 2021; 9: 65.","DOI":"10.1186\/s40478-021-01159-w"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Giustiniani J, Chambraud B, Sardin E, Dounane O, Guillemeau K, Nakatani H, et al. Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111: 4584\u20134589.","DOI":"10.1073\/pnas.1402645111"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Wang C, Terrigno M, Li J, Distler T, Pandya NJ, Ebeling M, et al. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation. Neuron. 2023; 111: 2660\u20132674.e9.","DOI":"10.1016\/j.neuron.2023.05.033"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Meduri G, Guillemeau K, Dounane O, Sazdovitch V, Duyckaerts C, Chambraud B, et al. Caspase-cleaved Tau-D(421) is colocalized with the immunophilin FKBP52 in the autophagy-endolysosomal system of Alzheimer\u2019s disease neurons. Neurobiology of Aging. 2016; 46: 124\u2013137.","DOI":"10.1016\/j.neurobiolaging.2016.06.017"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Giustiniani J, Guillemeau K, Dounane O, Sardin E, Huvent I, Schmitt A, et al. The FK506-binding protein FKBP52 in vitro induces aggregation of truncated Tau forms with prion-like behavior. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2015; 29: 3171\u20133181.","DOI":"10.1096\/fj.14-268243"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Chambraud B, Byrne C, Meduri G, Baulieu EE, Giustiniani J. FKBP52 in Neuronal Signaling and Neurodegenerative Diseases: A Microtubule Story. International Journal of Molecular Sciences. 2022; 23: 1738.","DOI":"10.3390\/ijms23031738"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Zhang ZY, Harischandra DS, Wang R, Ghaisas S, Zhao JY, McMonagle TP, et al. TRIM11 protects against tauopathies and is down-regulated in Alzheimer\u2019s disease. Science (New York, N.Y.). 2023; 381: eadd6696.","DOI":"10.1126\/science.add6696"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Valentino RR, Koga S, Heckman MG, Brushaber DE, Diehl NN, Walton RL, et al. Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy. Movement Disorders: Official Journal of the Movement Disorder Society. 2020; 35: 890\u2013894.","DOI":"10.1002\/mds.28010"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. The Journal of Biological Chemistry. 2009; 284: 12845\u201312852.","DOI":"10.1074\/jbc.M808759200"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Dujardin S, L\u00e9colle K, Caillierez R, B\u00e9gard S, Zommer N, Lachaud C, et al. Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathologica Communications. 2014; 2: 14.","DOI":"10.1186\/2051-5960-2-14"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Wang Y, Balaji V, Kaniyappan S, Kr\u00fcger L, Irsen S, Tepper K, et al. The release and trans-synaptic transmission of Tau via exosomes. Molecular Neurodegeneration. 2017; 12: 5.","DOI":"10.1186\/s13024-016-0143-y"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, et al. Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. The Journal of Biological Chemistry. 2013; 288: 1856\u20131870.","DOI":"10.1074\/jbc.M112.394528"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Crotti A, Sait HR, McAvoy KM, Estrada K, Ergun A, Szak S, et al. BIN1 favors the spreading of Tau via extracellular vesicles. Scientific Reports. 2019; 9: 9477.","DOI":"10.1038\/s41598-019-45676-0"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020; 580: 381\u2013385.","DOI":"10.1038\/s41586-020-2156-5"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Cooper JM, Lathuiliere A, Migliorini M, Arai AL, Wani MM, Dujardin S, et al. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. The Journal of Biological Chemistry. 2021; 296: 100715.","DOI":"10.1016\/j.jbc.2021.100715"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Martini-Stoica H, Cole AL, Swartzlander DB, Chen F, Wan YW, Bajaj L, et al. TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. The Journal of Experimental Medicine. 2018; 215: 2355\u20132377.","DOI":"10.1084\/jem.20172158"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Xu Y, Du S, Marsh JA, Horie K, Sato C, Ballabio A, et al. TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. Molecular Psychiatry. 2021; 26: 5925\u20135939.","DOI":"10.1038\/s41380-020-0738-0"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer\u2019s Research & Therapy. 2022; 14: 191.","DOI":"10.1186\/s13195-022-01124-2"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023; 330: 512\u2013527.","DOI":"10.1001\/jama.2023.21109"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"del Ser T, Steinwachs KC, Gertz HJ, Andr\u00e9s MV, G\u00f3mez-Carrillo B, Medina M, et al. Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a pilot study. Journal of Alzheimer\u2019s Disease: JAD. 2013; 33: 205\u2013215.","DOI":"10.3233\/JAD-2012-120805"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"Lovestone S, Boada M, Dubois B, H\u00fcll M, Rinne JO, Huppertz HJ, et al. A phase II trial of tideglusib in Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Disease: JAD. 2015; 45: 75\u201388.","DOI":"10.3233\/JAD-141959"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"Georgievska B, Sandin J, Doherty J, M\u00f6rtberg A, Neelissen J, Andersson A, et al. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. Journal of Neurochemistry. 2013; 125: 446\u2013456.","DOI":"10.1111\/jnc.12203"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. The British Journal of Psychiatry: the Journal of Mental Science. 2011; 198: 351\u2013356.","DOI":"10.1192\/bjp.bp.110.080044"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"Devanand DP, Crocco E, Forester BP, Husain MM, Lee S, Vahia IV, et al. Low Dose Lithium Treatment of Behavioral Complications in Alzheimer\u2019s Disease: Lit-AD Randomized Clinical Trial. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry. 2022; 30: 32\u201342.","DOI":"10.1016\/j.jagp.2021.04.014"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"Hampel H, Ewers M, B\u00fcrger K, Annas P, M\u00f6rtberg A, Bogstedt A, et al. Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. The Journal of Clinical Psychiatry. 2009; 70: 922\u2013931.","DOI":"10.4088\/JCP.08m04606"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer\u2019s disease. Current Alzheimer Research. 2013; 10: 104\u2013107.","DOI":"10.2174\/156720513804871354"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Scheltens P, Prins N, Lammertsma A, Yaqub M, Gouw A, Wink AM, et al. An exploratory clinical study of p38\u03b1 kinase inhibition in Alzheimer\u2019s disease. Annals of Clinical and Translational Neurology. 2018; 5: 464\u2013473.","DOI":"10.1002\/acn3.549"},{"key":"ref120","doi-asserted-by":"crossref","unstructured":"Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P, et al. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2021; 13: 106.","DOI":"10.1186\/s13195-021-00843-2"},{"key":"ref121","doi-asserted-by":"crossref","unstructured":"Briner A, G\u00f6tz J, Polanco JC. Fyn Kinase Controls Tau Aggregation In Vivo. Cell Reports. 2020; 32: 108045.","DOI":"10.1016\/j.celrep.2020.108045"},{"key":"ref122","doi-asserted-by":"crossref","unstructured":"Nygaard HB. Targeting Fyn Kinase in Alzheimer\u2019s Disease. Biological Psychiatry. 2018; 83: 369\u2013376.","DOI":"10.1016\/j.biopsych.2017.06.004"},{"key":"ref123","doi-asserted-by":"crossref","unstructured":"Kaufman AC, Salazar SV, Haas LT, Yang J, Kostylev MA, Jeng AT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Annals of Neurology. 2015; 77: 953\u2013971.","DOI":"10.1002\/ana.24394"},{"key":"ref124","doi-asserted-by":"crossref","unstructured":"Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, et al. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2015; 7: 35.","DOI":"10.1186\/s13195-015-0119-0"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, G\u00f6tz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer\u2019s disease models. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107: 13888\u201313893.","DOI":"10.1073\/pnas.1009038107"},{"key":"ref126","doi-asserted-by":"crossref","unstructured":"Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, et al. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer\u2019s disease model. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia. 2010; 17: 1025\u20131033.","DOI":"10.1016\/j.jocn.2010.04.020"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, et al. A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s Disease: JAD. 2016; 54: 223\u2013232.","DOI":"10.3233\/JAD-160544"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Cardoso BR, Roberts BR, Malpas CB, Vivash L, Genc S, Saling MM, et al. Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer\u2019s Disease. Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics. 2019; 16: 192\u2013202.","DOI":"10.1007\/s13311-018-0662-z"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart FR, et al. Antisense reduction of tau in adult mice protects against seizures. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2013; 33: 12887\u201312897.","DOI":"10.1523\/JNEUROSCI.2107-13.2013"},{"key":"ref130","doi-asserted-by":"crossref","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nature Medicine. 2023; 29: 1437\u20131447.","DOI":"10.1038\/s41591-023-02326-3"},{"key":"ref131","unstructured":"West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, et al. Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer\u2019s Disease and Other Tauopathies. The Journal of Prevention of Alzheimer\u2019s Disease. 2017; 4: 236\u2013241."},{"key":"ref132","doi-asserted-by":"crossref","unstructured":"Florian H, Wang D, Arnold SE, Boada M, Guo Q, Jin Z, et al. Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study. Brain: a Journal of Neurology. 2023; 146: 2275\u20132284.","DOI":"10.1093\/brain\/awad024"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, et al. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer\u2019s disease. Science Translational Medicine. 2021; 13: eabb2639.","DOI":"10.1126\/scitranslmed.abb2639"},{"key":"ref134","doi-asserted-by":"crossref","unstructured":"Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, et al. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurology. 2022; 79: 758\u2013767.","DOI":"10.1001\/jamaneurol.2022.1375"},{"key":"ref135","doi-asserted-by":"crossref","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, et al. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet. Neurology. 2023; 101: e1391\u2013e1401.","DOI":"10.1212\/WNL.0000000000207663"},{"key":"ref136","doi-asserted-by":"crossref","unstructured":"Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nature Aging. 2021; 1: 521\u2013534.","DOI":"10.1038\/s43587-021-00070-2"},{"key":"ref137","doi-asserted-by":"crossref","unstructured":"Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2018; 10: 108.","DOI":"10.1186\/s13195-018-0436-1"},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet. Neurology. 2017; 16: 123\u2013134.","DOI":"10.1016\/S1474-4422(16)30331-3"},{"key":"ref139","doi-asserted-by":"crossref","unstructured":"Galasko D. Active immunization in Alzheimer\u2019s disease. Nature Aging. 2021; 1: 493\u2013495.","DOI":"10.1038\/s43587-021-00076-w"},{"key":"ref140","doi-asserted-by":"crossref","unstructured":"Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behavioural Pharmacology. 2015; 26: 353\u2013368.","DOI":"10.1097\/FBP.0000000000000133"},{"key":"ref141","doi-asserted-by":"crossref","unstructured":"Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JMD, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease. Journal of Alzheimer\u2019s Disease: JAD. 2015; 44: 705\u2013720.","DOI":"10.3233\/JAD-142874"},{"key":"ref142","doi-asserted-by":"crossref","unstructured":"Riedel G, Klein J, Niewiadomska G, Kondak C, Schwab K, Lauer D, et al. Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Current Alzheimer Research. 2020; 17: 285\u2013296.","DOI":"10.2174\/1567205017666200224120926"},{"key":"ref143","doi-asserted-by":"crossref","unstructured":"Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO. Oral Tau Aggregation Inhibitor for Alzheimer\u2019s Disease: Design, Progress and Basis for Selection of the 16 mg\/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. The Journal of Prevention of Alzheimer\u2019s Disease. 2022; 9: 780\u2013790.","DOI":"10.14283\/jpad.2022.63"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet (London, England). 2016; 388: 2873\u20132884.","DOI":"10.1016\/S0140-6736(16)31275-2"},{"key":"ref145","doi-asserted-by":"crossref","unstructured":"Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer\u2019s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. Journal of Alzheimer\u2019s Disease: JAD. 2018; 61: 435\u2013457.","DOI":"10.3233\/JAD-170560"},{"key":"ref146","doi-asserted-by":"crossref","unstructured":"Mullard A. Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure. Nature Reviews. Drug Discovery. 2016; 15: 591\u2013592.","DOI":"10.1038\/nrd.2016.176"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/23\/11\/10.31083\/j.jin2311197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:42:50Z","timestamp":1732707770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/23\/11\/10.31083\/j.jin2311197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":146,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"alternative-id":["S0219-6352(24)00808-8"],"URL":"https:\/\/doi.org\/10.31083\/j.jin2311197","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"197"}}